Ken Griffin Anixa Biosciences Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.21 - $3.48 $46,410 - $73,080	21,000 New	21,000 $66,000
Q1 2024 May 15, 2024	BUY	$3.08 - $5.02 $17,248 - $28,111	5,600 Added 62.92%	14,500 $45,000
Q4 2023 Feb 14, 2024	SELL	$2.85 - $4.19 $29,070 - $42,738	-10,200 Reduced 53.4%	8,900 $34,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.87 $18,117 - $23,607	6,100 Added 46.92%	19,100 $62,000
Q2 2023 Aug 14, 2023	BUY	$3.0 - $5.97 $16,200 - $32,238	5,400 Added 71.05%	13,000 $41,000
Q1 2023 May 15, 2023	SELL	$3.86 - $5.0 $1,158 - $1,500	-300 Reduced 3.8%	7,600 $32,000
Q4 2022 Feb 14, 2023	BUY	$3.78 - $5.81 $29,862 - $45,899	7,900 New	7,900 $33,000

5.56M

21K

6.7K

Ticker ANIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,661,700
Market Cap $78.5M
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.